References
- McLaughlin JM, Khan F, Begier E, et al. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac300.
- European Medicines Agency. First vaccine to protect older adults from respiratory syncytial virus (RSV) infection; 2023 [updated 2023 Apr 26; 2024 Jun 12]. Available from: https://www.ema.europa.eu/en/news/first-vaccine-protect-older-adults-respiratory-syncytial-virus-rsv-infection
- World Health Organization. Respiratory Syncytial Virus (RSV) disease; 2024 [2024 Mar 07]. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/respiratory-syncytial-virus-disease
- Surie D, Yuengling KA, DeCuir J, et al. Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged >/=60 years – IVY Network, 20 U.S. States, February 2022-May 2023. MMWR Morb Mortal Wkly Rep. 2023;72(40):1083–1088. doi: 10.15585/mmwr.mm7240a2.
- Branche AR, Saiman L, Walsh EE, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Influenza Other Respir Viruses. 2022;16(6):1151–1160. doi: 10.1111/irv.13043.
- Goldman CR, Sieling WD, Alba LR, et al. Severe clinical outcomes among adults hospitalized with respiratory syncytial virus infections, New York City, 2017-2019. Public Health Rep. 2022;137(5):929–935. doi: 10.1177/00333549211041545.
- Carrico J, Hicks KA, Wilson E, et al. The annual economic burden of respiratory syncytial virus in adults in the United States. J Infect Dis. 2023;jiad559. doi: 10.1093/infdis/jiad559.
- Centers for Disease Control and Prevention. Respiratory Syncytial Virus (RSV) Vaccine VIS: Centers for Disease Control and Prevention; 2023 [updated 2023 Oct 19; cited 2024 Apr 08]. Available from: https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.html#:∼:text=CDC%20recommends%20a%20single%20dose,most%20of%20the%20United%20States
- AREXVY [package insert]. Durham (NC): GlaxoSmithKline; 2023.
- ABRYSVO™ [package insert]. New York (NY): Pfizer Inc; 2023.
- US Food and Drug Administration. BLA Approval Cambridge, MA; 2024 [cited 2024 Jun 12]. Available from: https://www.fda.gov/media/179015/download?attachment
- SPIKEVAX [package insert]. Cambridge (MA): ModernaTX, Inc; 2022.
- Cuesta Esteve I, Fernández Fernández P, López Palacios S, et al. Health care professionals’ preference for a fully liquid, ready-to-use hexavalent vaccine in Spain. Prev Med Rep. 2021;22:101376. doi: 10.1016/j.pmedr.2021.101376.
- Mehta DK-CS, Krivelyova A, Yu WW, et al. Vaccine time, cost and preference comparison between pre-filled syringe formulations and vaccines that require reconstitution: a targeted literature review. Poster session presented at: ISPOR EU 2023 Nov 12–15; Copenhagen, Denmark.
- De Coster I, Fournie X, Faure C, et al. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976–3982. doi: 10.1016/j.vaccine.2015.06.030.
- Aljunid SM, Al Bashir L, Ismail AB, et al. Economic impact of switching from partially combined vaccine "Pentaxim(R) and hepatitis B" to fully combined vaccine "Hexaxim(R)" in the Malaysian National Immunization Program. BMC Health Serv Res. 2022;22(1):34.
- Icardi G, Orsi A, Vitali Rosati G, et al. Preferences of healthcare professionals regarding hexavalent pediatric vaccines in Italy: a survey of attitudes and expectations. J Prev Med Hyg. 2020;61(3):E424–E444.
- Lee YH, Harris RC, Oh HW, et al. Vaccine-related errors in reconstitution in South Korea: a national physicians’ and nurses’ survey. Vaccines (Basel). 2021;9(2):117. doi: 10.3390/vaccines9020117.
- Lloyd AJ, Nafees B, Ziani E, et al. What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution? Patient Prefer Adherence. 2015;9:1517–1524. doi: 10.2147/PPA.S87229.
- Finkler SA, Knickman JR, Hendrickson G, et al. A comparison of work-sampling and time-and-motion techniques for studies in health services research. Health Serv Res. 1993;28(5):577–597.
- Cohen JE. Statistical power analysis for the behavioral sciences. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc; 1988.
- Lehmann EL. Nonparametrics: statistical methods based on ranks. Saddle River, (NJ): Prentice Hall; 1998.
- IQVIA Institute. Trends in Vaccine Administration in the United States: IQVIA Inc.; 2023 [updated 2023 Jan 13; cited 2024 Apr 08]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/trends-in-vaccine-administration-in-the-united-states
- IQVIA Institute. Trends in global adult vaccination: impact of COVID-19: IQVIA, Inc.; 2023 [updated 2023 Jul 18; cited 2024 Apr 08]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/trends-in-global-adult-vaccination
- Patel SK, Kelm MJ, Bush PW, et al. Prevalence and risk factors of burnout in community pharmacists. J Am Pharm Assoc. 2021;61(2):145–150. doi: 10.1016/j.japh.2020.09.022.
- Centers for Disease Control and Prevention. RSV vaccination coverage, adults 65 years and older, United States: Centers for Disease Control and Prevention; 2024 [updated 2024 Mar 5; cited 2024 Apr 10]. Available from: https://www.cdc.gov/vaccines/imz-managers/coverage/rsvvaxview/adults-65yrs-older-coverage.html
- Centers for Disease Control and Prevention. Seasonal flu vaccines: Centers for Disease Control and Prevention; 2024 [updated 2024 Mar 12; cited 2024 Apr 10]. Available from: https://www.cdc.gov/flu/prevent/flushot.htm
- Centers for Disease Control and Prevention. Influenza vaccinations administered in pharmacies and physician medical offices, adults, United States: Centers for Disease Control and Prevention; 2024 [cited 2024 Apr 10]. Available from: https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-administered.html
- Golbach AP, McCullough KB, Soefje SA, et al. Evaluation of burnout in a national sample of hematology-oncology pharmacists. J Clin Oncol Oncol Pract. 2022;18(8):e1278–e1288. doi: 10.1200/OP.21.00471.
- Skrupky LP, West CP, Shanafelt T, et al. Ability of the Well-Being Index to identify pharmacists in distress. J Am Pharm Assoc. 2020;60(6):906–914.e2. doi: 10.1016/j.japh.2020.06.015.